BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/14/2020 11:33:23 AM | Browse: 857 | Download: 2001
 |
Received |
|
2020-05-28 15:11 |
|
Peer-Review Started |
|
2020-05-28 15:12 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-08-09 03:33 |
|
Revised |
|
2020-08-11 21:56 |
|
Second Decision |
|
2020-09-16 12:04 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-09-17 04:55 |
|
Articles in Press |
|
2020-09-17 04:55 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-10-14 00:48 |
|
Publish the Manuscript Online |
|
2020-10-14 11:33 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations?
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mohammadreza Abdollahi, Neda Khalilian Ekrami, Morteza Ghojazadeh, H Marike Boezen, Mohammadhossein Somi and Behrooz Z Alizadeh |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mohammadreza Abdollahi, MD, PhD, Doctor, Doctor, Department of Epidemiology, University of Groningen, Hanzeplein1, Groningen 9700 RB, Netherlands. m.abdollahi@umcg.nl |
| Key Words |
Autoimmune hepatitis; Efficacy; Grading of Recommendations Assessment, Development and Evaluation approach; Systematic review; Meta-analysis; Second-line |
| Core Tip |
There is no consensus in the literature on which second-line treatment is superior in autoimmune hepatitis (AIH). This is the first systematic review and meta-analysis to compare the efficacy and safety of tacrolimus and mycophenolate mofetil (MMF) as second-line treatments in AIH. We also evaluated the quality of evidence for adding to the clinical guidelines for routine practice. We conclude that tacrolimus and MMF are considered effective for patients who are non-responders or intolerant to first-line treatment, but the quality of evidence is not high and it is questionable if these results should be added to clinical guidelines for AIH. |
| Publish Date |
2020-10-14 11:33 |
| Citation |
Abdollahi M, Khalilian Ekrami N, Ghojazadeh M, Boezen HM, Somi M, Alizadeh BZ. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations? World J Gastroenterol 2020; 26(38): 5896-5910 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i38/5896.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i38.5896 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
